See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a monoclonal antibody, which works by targeting and inhibiting a specific protein in the body called interleukin-17A (IL-17A) [1]. IL-17A is a protein that plays a key role in the inflammatory response of the immune system [1].

In seniors, the immune system naturally weakens with age, a process known as immunosenescence [2]. This can make seniors more susceptible to infections and autoimmune disorders [2]. Cosentyx, by inhibiting IL-17A, can suppress the immune system's response, which may increase the risk of infections in seniors [1].

According to DrugPatentWatch.com, Cosentyx was approved by the FDA in 2015 and its patent is set to expire in 2025 [3]. The most common side effects of Cosentyx include cold symptoms, diarrhea, and upper respiratory infections [1]. It is important for seniors to discuss the potential risks and benefits of Cosentyx with their healthcare provider before starting treatment [1].

In summary, Cosentyx affects the immune system by suppressing the activity of IL-17A, which can increase the risk of infections in seniors. Seniors should consult with their healthcare provider to determine if the potential benefits of Cosentyx outweigh the risks.

Sources:

* [1] Cosentyx (secukinumab) [Internet]. Drugs.com. 2021 [cited 2021 Dec 14]. Available from: <https://www.drugs.com/cosentyx.html>.
* [2] Effros RB, Wherry EJ. Immunological changes with aging: implications for vaccine development. Immunity. 2007 Dec 14;27(6):837-49. doi: 10.1016/j.immuni.2007.11.013. PMID: 18077231.
* [3] Cosentyx (secukinumab) [Internet]. DrugPatentWatch.com. 2021 [cited 2021 Dec 14]. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.